aTyr Pharma, Inc. (LIFE) Cut to “Hold” at Zacks Investment Research
aTyr Pharma, Inc. (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
Other analysts have also recently issued reports about the company. ValuEngine raised aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. BMO Capital Markets reissued a “hold” rating on shares of aTyr Pharma in a research report on Wednesday, May 24th. Finally, Piper Jaffray Companies started coverage on aTyr Pharma in a research report on Thursday, September 7th. They issued an “overweight” rating and a $7.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $4.27.
aTyr Pharma (NASDAQ:LIFE) traded up 12.12% on Thursday, hitting $3.70. The stock had a trading volume of 219,556 shares. The company’s market cap is $88.20 million. aTyr Pharma has a 1-year low of $2.10 and a 1-year high of $4.45. The stock has a 50 day moving average price of $3.26 and a 200 day moving average price of $3.45.
aTyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.06. On average, equities research analysts expect that aTyr Pharma will post ($2.18) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/16/atyr-pharma-inc-life-cut-to-hold-at-zacks-investment-research.html.
In other aTyr Pharma news, CEO John Mendlein acquired 37,736 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were acquired at an average cost of $2.65 per share, with a total value of $100,000.40. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Paul Schimmel acquired 94,336 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was acquired at an average cost of $2.65 per share, for a total transaction of $249,990.40. Following the completion of the transaction, the director now directly owns 40,440 shares in the company, valued at approximately $107,166. The disclosure for this purchase can be found here. Corporate insiders own 33.30% of the company’s stock.
An institutional investor recently raised its position in aTyr Pharma stock. EcoR1 Capital LLC grew its position in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) by 134.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,292,659 shares of the biotechnology company’s stock after buying an additional 1,315,673 shares during the quarter. aTyr Pharma accounts for approximately 2.0% of EcoR1 Capital LLC’s holdings, making the stock its 13th largest position. EcoR1 Capital LLC owned approximately 9.65% of aTyr Pharma worth $8,024,000 at the end of the most recent reporting period. 46.66% of the stock is owned by institutional investors and hedge funds.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.